AR076767A1 - Procedimiento para provocar una respuesta inmunitaria reforzada en especies aviares - Google Patents
Procedimiento para provocar una respuesta inmunitaria reforzada en especies aviaresInfo
- Publication number
- AR076767A1 AR076767A1 ARP100101647A ARP100101647A AR076767A1 AR 076767 A1 AR076767 A1 AR 076767A1 AR P100101647 A ARP100101647 A AR P100101647A AR P100101647 A ARP100101647 A AR P100101647A AR 076767 A1 AR076767 A1 AR 076767A1
- Authority
- AR
- Argentina
- Prior art keywords
- avian
- immune response
- avian species
- nucleic acid
- immunomodulatory composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- 230000028993 immune response Effects 0.000 title abstract 7
- 241000894007 species Species 0.000 title 1
- 241000271566 Aves Species 0.000 abstract 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 8
- 230000002519 immonomodulatory effect Effects 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- 235000012000 cholesterol Nutrition 0.000 abstract 4
- 239000003124 biologic agent Substances 0.000 abstract 3
- 125000002091 cationic group Chemical group 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 230000002458 infectious effect Effects 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- VVOIQBFMTVCINR-WWMZEODYSA-N 11-deoxycorticosterone pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]1(C)CC2 VVOIQBFMTVCINR-WWMZEODYSA-N 0.000 abstract 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010006811 Bursitis Diseases 0.000 abstract 1
- 206010008631 Cholera Diseases 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 208000002979 Influenza in Birds Diseases 0.000 abstract 1
- 208000006758 Marek Disease Diseases 0.000 abstract 1
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 abstract 1
- 208000010359 Newcastle Disease Diseases 0.000 abstract 1
- 241000702263 Reovirus sp. Species 0.000 abstract 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 abstract 1
- 206010044302 Tracheitis Diseases 0.000 abstract 1
- 241000132980 Turkey adenovirus 3 Species 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 241000701792 avian adenovirus Species 0.000 abstract 1
- 206010064097 avian influenza Diseases 0.000 abstract 1
- 208000004668 avian leukosis Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 230000005934 immune activation Effects 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 201000009837 laryngotracheitis Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
Abstract
La presente solicitud se refiere a un procedimiento de activacion inmunitaria que es eficaz para provocar una respuesta inmunitaria no específica de antígeno en un miembro de la especie aviar. Reivindicacion 1: Un procedimiento para provocar una respuesta inmunitaria en al menos un miembro de la especie aviar que comprende administrar al miembro de la especie aviar una cantidad eficaz de una composicion inmunomoduladora para provocar una respuesta inmunitaria en el miembro de la especie aviar, en el que la composicion inmunomoduladora comprende: a) un vehículo de liberacion liposomico cationico; y b) una molécula de ácido nucleico. Reivindicacion 3: El procedimiento de la reivindicacion 1, en el que el vehículo de liberacion liposomico comprende pares de lípidos seleccionados del grupo constituido por DTMA y colesterol; DOTAP y colesterol: DOTIM y colesterol, y DDAB y colesterol. Reivindicacion 4: El procedimiento de la reivindicacion 1, en el que la molécula de ácido nucleico es un vector aislado de ácido nucleico derivado de bacteria sin un inserto génico o un fragmento del mismo. Reivindicacion 7: El procedimiento de la reivindicacion 1, en el que la composicion inmunomoduladora comprende además un agente biologico. Reivindicacion 9: El procedimiento de la reivindicacion 7, en el que el agente biologico es una vacuna para una enfermedad seleccionada del grupo constituido por enfermedad de Marek, enfermedad de New Castle, anemia del pollo, enfermedad de la bursitis infecciosa, bronquitis infecciosa, herpesvirus de pavo, laringotraqueítis infecciosa, encefalomielitis aviar, viruela aviar, colera aviar, gripe aviar, reovirus, leucosis aviar, reticuloendoteliosis, adenovirus aviar, virus de la enteritis hemorrágica y sus combinaciones. Reivindicacion 10: Un procedimiento para provocar una respuesta inmunitaria en un miembro de la especie aviar que comprende administrar al miembro de la especie aviar una cantidad eficaz de una composicion inmunomoduladora para provocar una respuesta inmunitaria en el miembro de la especie aviar, en el que la composicion inmunomoduladora comprende: a) un vehículo de liberacion liposomico cationico; b) una molécula de ácido nucleico, siendo la molécula de ácido nucleico un vector aislado de ácido nucleico derivado de bacterias sin un inserto génico, o un fragmento del mismo; y c) un agente biologico. Reivindicacion 18: Un procedimiento para provocar una respuesta inmunitaria no específica de antígeno en un miembro de la especie aviar que comprende administrar al miembro de la especie aviar una cantidad eficaz de una composicion inmunomoduladora para provocar una respuesta inmunitaria en el miembro de la especie aviar, en el que la composicion inmunomoduladora comprende: a) un vehículo de liberacion liposomico cationico; y b) una molécula de ácido nucleico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17809909P | 2009-05-14 | 2009-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076767A1 true AR076767A1 (es) | 2011-07-06 |
Family
ID=42357738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101647A AR076767A1 (es) | 2009-05-14 | 2010-05-12 | Procedimiento para provocar una respuesta inmunitaria reforzada en especies aviares |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20120064151A1 (es) |
| EP (2) | EP2992899B1 (es) |
| JP (1) | JP5679589B2 (es) |
| KR (2) | KR20170102379A (es) |
| CN (2) | CN102427827B (es) |
| AR (1) | AR076767A1 (es) |
| AU (1) | AU2010246652B2 (es) |
| BR (1) | BRPI1010803A2 (es) |
| CA (1) | CA2761736C (es) |
| CL (1) | CL2011002808A1 (es) |
| CO (1) | CO6460752A2 (es) |
| CR (1) | CR20110595A (es) |
| DK (2) | DK2992899T3 (es) |
| EC (1) | ECSP11011448A (es) |
| ES (2) | ES2808827T3 (es) |
| HR (2) | HRP20151117T1 (es) |
| HU (2) | HUE025765T2 (es) |
| IL (1) | IL215900A (es) |
| LT (1) | LT2992899T (es) |
| MX (1) | MX336019B (es) |
| MY (1) | MY162561A (es) |
| NI (1) | NI201100196A (es) |
| NZ (1) | NZ596366A (es) |
| PE (1) | PE20120903A1 (es) |
| PL (2) | PL2429581T3 (es) |
| PT (2) | PT2429581E (es) |
| RU (1) | RU2570732C9 (es) |
| SI (2) | SI2429581T1 (es) |
| SV (1) | SV2011004056A (es) |
| TW (1) | TWI555846B (es) |
| UA (1) | UA106076C2 (es) |
| UY (1) | UY32634A (es) |
| WO (1) | WO2010130374A1 (es) |
| ZA (1) | ZA201107827B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5759890B2 (ja) * | 2008-03-25 | 2015-08-05 | ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強 |
| BR112013016231B1 (pt) * | 2010-12-22 | 2021-03-23 | Bayer Intellectual Property Gmbh | Composição imunomoduladora para o tratamento de doença respiratória bovina |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| CN103721253B (zh) * | 2014-01-02 | 2015-06-10 | 青岛易邦生物工程有限公司 | 一种禽脑脊髓炎和鸡痘二联活疫苗 |
| CA2940794C (en) * | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
| WO2016207314A2 (en) * | 2015-06-26 | 2016-12-29 | Bayer Animal Health Gmbh | Methods of modulating cytosolic dna surveillance molecules |
| EP3328423B1 (en) * | 2015-07-31 | 2021-05-26 | Bayer Animal Health GmbH | Enhanced immune response in fish |
| AU2016302436B2 (en) * | 2015-07-31 | 2022-03-03 | Elanco Animal Health Gmbh | Enhanced immune response in porcine species |
| AU2017301528A1 (en) | 2016-07-26 | 2019-02-14 | Elanco Animal Health Gmbh | Increased fertility in bovine species |
| US11932857B2 (en) * | 2017-12-15 | 2024-03-19 | Elanco Animal Health Gmbh | Immunostimulatory oligonucleotides |
| CN114467855A (zh) * | 2022-01-14 | 2022-05-13 | 广东海大集团股份有限公司 | 一种多病因气囊炎雏鸡模型的构建方法及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4458630A (en) * | 1982-06-22 | 1984-07-10 | The United States Of America As Represented By The Secretary Of Agriculture | Disease control in avian species by embryonal vaccination |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| CA2395840A1 (en) * | 1999-12-27 | 2001-07-05 | The University Of Manitoba | Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens |
| US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| JP5759890B2 (ja) * | 2008-03-25 | 2015-08-05 | ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強 |
-
2010
- 2010-05-07 MX MX2011011931A patent/MX336019B/es unknown
- 2010-05-07 NZ NZ596366A patent/NZ596366A/en not_active IP Right Cessation
- 2010-05-07 LT LTEP15178476.6T patent/LT2992899T/lt unknown
- 2010-05-07 EP EP15178476.6A patent/EP2992899B1/en active Active
- 2010-05-07 ES ES15178476T patent/ES2808827T3/es active Active
- 2010-05-07 HU HUE10720350A patent/HUE025765T2/en unknown
- 2010-05-07 UA UAA201114824A patent/UA106076C2/uk unknown
- 2010-05-07 JP JP2012510144A patent/JP5679589B2/ja not_active Expired - Fee Related
- 2010-05-07 PT PT107203507T patent/PT2429581E/pt unknown
- 2010-05-07 MY MYPI2011005467A patent/MY162561A/en unknown
- 2010-05-07 BR BRPI1010803-3A patent/BRPI1010803A2/pt not_active Application Discontinuation
- 2010-05-07 KR KR1020177024103A patent/KR20170102379A/ko not_active Ceased
- 2010-05-07 HU HUE15178476A patent/HUE051005T2/hu unknown
- 2010-05-07 CA CA2761736A patent/CA2761736C/en active Active
- 2010-05-07 HR HRP20151117TT patent/HRP20151117T1/hr unknown
- 2010-05-07 DK DK15178476.6T patent/DK2992899T3/da active
- 2010-05-07 PT PT151784766T patent/PT2992899T/pt unknown
- 2010-05-07 KR KR1020117029865A patent/KR101966989B1/ko not_active Expired - Fee Related
- 2010-05-07 RU RU2011150529/15A patent/RU2570732C9/ru active
- 2010-05-07 CN CN201080021073.9A patent/CN102427827B/zh active Active
- 2010-05-07 WO PCT/EP2010/002809 patent/WO2010130374A1/en not_active Ceased
- 2010-05-07 SI SI201031045T patent/SI2429581T1/sl unknown
- 2010-05-07 CN CN201510317838.8A patent/CN104906573A/zh active Pending
- 2010-05-07 PE PE2011001938A patent/PE20120903A1/es not_active Application Discontinuation
- 2010-05-07 SI SI201032031T patent/SI2992899T1/sl unknown
- 2010-05-07 PL PL10720350T patent/PL2429581T3/pl unknown
- 2010-05-07 EP EP10720350.7A patent/EP2429581B1/en not_active Not-in-force
- 2010-05-07 AU AU2010246652A patent/AU2010246652B2/en active Active
- 2010-05-07 DK DK10720350.7T patent/DK2429581T3/en active
- 2010-05-07 ES ES10720350.7T patent/ES2550181T3/es active Active
- 2010-05-07 US US13/320,289 patent/US20120064151A1/en not_active Abandoned
- 2010-05-07 PL PL15178476T patent/PL2992899T3/pl unknown
- 2010-05-12 TW TW099115052A patent/TWI555846B/zh not_active IP Right Cessation
- 2010-05-12 UY UY0001032634A patent/UY32634A/es not_active Application Discontinuation
- 2010-05-12 AR ARP100101647A patent/AR076767A1/es unknown
-
2011
- 2011-10-25 IL IL215900A patent/IL215900A/en active IP Right Grant
- 2011-10-26 ZA ZA2011/07827A patent/ZA201107827B/en unknown
- 2011-11-10 CL CL2011002808A patent/CL2011002808A1/es unknown
- 2011-11-10 SV SV2011004056A patent/SV2011004056A/es unknown
- 2011-11-10 EC EC2011011448A patent/ECSP11011448A/es unknown
- 2011-11-11 NI NI201100196A patent/NI201100196A/es unknown
- 2011-11-11 CR CR20110595A patent/CR20110595A/es unknown
- 2011-11-11 CO CO11153951A patent/CO6460752A2/es not_active Application Discontinuation
-
2020
- 2020-09-29 HR HRP20201554TT patent/HRP20201554T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076767A1 (es) | Procedimiento para provocar una respuesta inmunitaria reforzada en especies aviares | |
| RU2484136C2 (ru) | Способ получения вируса гриппа | |
| Swayne et al. | Strategies and challenges for eliciting immunity against avian influenza virus in birds | |
| Sylte et al. | Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection | |
| EP1874918B1 (en) | Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines | |
| Knuschke et al. | Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection | |
| Lee et al. | H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals | |
| Li et al. | Recombinant herpesvirus of turkeys as a vector-based vaccine against highly pathogenic H7N1 avian influenza and Marek's disease | |
| Steensels et al. | Prime–boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI | |
| Beato et al. | A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1 | |
| PT1951299E (pt) | Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores | |
| Loke et al. | Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes | |
| CN105148268A (zh) | 包含存于水相中的抗原和佐剂的乳剂疫苗组合物及其用途 | |
| Sun et al. | Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus | |
| Weyer et al. | Poxvirus-vectored vaccines for rabies—a review | |
| US20230158138A1 (en) | Modified gene vaccines against avian coronaviruses and methods of using the same | |
| Kilany et al. | Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus | |
| AU2016282761A1 (en) | Inactivated canine influenza vaccines and methods of making and uses thereof | |
| Kim et al. | Heterologous prime-boost immunization of Newcastle disease virus vectored vaccines protected broiler chickens against highly pathogenic avian influenza and Newcastle disease viruses | |
| Kapczynski et al. | Development of a virosome vaccine for Newcastle disease virus | |
| CA2744348C (en) | Recombinant inactivated viral vector vaccine | |
| BR112016001686B1 (pt) | Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição | |
| Wang et al. | Glycoprotein from street rabies virus BD06 induces early and robust immune responses when expressed from a non-replicative adenovirus recombinant | |
| KR20230040345A (ko) | 면역 반응을 유도하기 위한 면역원성 구축물, 조성물 및 방법 | |
| Salama et al. | Field application for experimental inactivated multivalent P. multocida and Avian Influenza (H9N2) vaccine in poultry. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |